A Patient Cohort With Locally Advanced or Metastatic Non-small Cell Lung Cancer Treated With Tarceva (Erlotinib) Monotherapy and Not Progressing After at Least 9 Months

Hoffmann-La Roche0 个研究点目标入组 217 人开始时间: 2010年6月最近更新: 2016年11月2日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方: Hoffmann-La Roche
入组人数: 217
主要终点: Progression-free survival

研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

This prospective, multi-center, observational study will assess the progression-free survival and safety of patients with locally advanced or metastatic non-small cell lung cancer treated with Tarceva (erlotinib) and not disease progressing after at least 9 months. Data will be collected for 24 months.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Prospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Adult patients, >/=18 years of age
•Diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC, stage III/IV)
•Treatment with Tarceva monotherapy and not progressing after at least 9 months at the date of study start

排除标准

•Not agreeing to be followed-up (for a maximum of 24 months)

结局指标

主要结局

Progression-free survival

时间窗: 24 months

次要结局

Overall survival(24 months)
Treatment compliance of patient(24 months)
Best treatment response(24 months)
Safety (incidence of adverse events)(24 months)
Type of treatment response(24 months)

研究者

发起方

Hoffmann-La Roche

申办方类型

Industry

责任方

Sponsor

相似试验

终止

3 期

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer PatientsNeoplasms, BreastCarcinoma of BreastHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastBRCA1 Gene MutationBRCA2 Gene MutationOvarian Neoplasms

NCT01905592Tesaro, Inc.216

已完成

不适用

Observational Study of Bevacizumab [Avastin] in Patients With Metastatic Colorectal Cancer (AVASTART)Colorectal Cancer

NCT01089413Hoffmann-La Roche201

已完成

不适用

ASPET Study: An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced Non-Small Cell Lung Cancer Harbouring EGFR Activating MutationsNon-Squamous Non-Small Cell Lung Cancer

NCT01723878Hoffmann-La Roche144

进行中（未招募）

不适用

Risk Factors and Long-term Impact of ICIsMalignant Neoplasm

NCT05754983First Affiliated Hospital Xi'an Jiaotong University1,000

招募中

3 期

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)Non-Small Cell Lung Cancer (NSCLC)

NCT05920356Amgen750